{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:00:22Z","timestamp":1789545622705,"version":"build-2803163510"},"reference-count":90,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1517\/14712598.2016.1118045","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T02:02:26Z","timestamp":1447725746000},"page":"173-186","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Novel approaches to biological therapy for psoriatic arthritis"],"prefix":"10.1517","volume":"16","author":[{"given":"Tristan","family":"Boyd","sequence":"first","affiliation":[{"name":",","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022\u2022) to readers."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000152"},{"key":"e_1_3_3_5_1","first-page":"210","article-title":"Psoriasis, psoriatic arthritis, or psoriatic disease?","volume":"33","author":"Scarpa R","year":"2006","unstructured":"Scarpa R, Ayala F, Caporaso N, et al. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol. 2006;33:210\u2013212.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg217"},{"key":"e_1_3_3_7_1","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman DD","year":"1990","unstructured":"Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809\u2013812.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg217"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg384"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-006-0064-9"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0191-y"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0242-4"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1031743"},{"key":"e_1_3_4_7_1","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin CT","year":"1998","unstructured":"Ritchlin CT, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544\u20131552.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S37606"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_3_5_3_1","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease PJ","year":"2006","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712\u2013721.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"e_1_3_6_4_1","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese MC","year":"2007","unstructured":"Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34:1040\u20131050.","journal-title":"J Rheumatol"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22379"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34436"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202035"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"e_1_3_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203697"},{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24128"},{"key":"e_1_3_9_4_1","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp K","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14:706\u2013714.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0359-0"},{"key":"e_1_3_9_8_1","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni CE","year":"2008","unstructured":"Antoni CE, Kavanaugh A, Van Der Heidje D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869\u2013876.","journal-title":"J Rheumatol"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045658"},{"key":"e_1_3_9_10_1","first-page":"S132","article-title":"Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure","volume":"65","author":"Mease PJ","year":"2013","unstructured":"Mease PJ, Fleischmann RM, Wollenhaupt J, et al. Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. Arthritis Rheum. 2013;65(Suppl):S132. Abstract 312.","journal-title":"Arthritis Rheum"},{"key":"e_1_3_9_11_1","first-page":"1908","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee E","year":"2004","unstructured":"Lee E, Trepicchio WL, Oestricher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:1908\u20131915.","journal-title":"J Exp Med"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3817"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"e_1_3_10_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204741"},{"key":"e_1_3_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03240.x"},{"key":"e_1_3_10_4_1","first-page":"S423","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, multicenter, double-blind, placebo-controlled study","volume":"66","author":"Mease P","year":"2014","unstructured":"Mease P, McInnes I, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 2014;66(Suppl):S423. Abstract 953.","journal-title":"Arthritis Rheum"},{"key":"e_1_3_10_5_1","first-page":"S424","article-title":"Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study","volume":"66","author":"Van Der Heijde D","year":"2014","unstructured":"Van Der Heijde D, Landewe R, Mease P, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2014;66(Suppl):S424. Abstract 954.","journal-title":"Arthritis Rheum"},{"key":"e_1_3_10_6_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interluekin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"McInnes IB","year":"2015","unstructured":"McInnes IB, Mease P, Kirkham B, et al. Secukinumab, a human anti-interluekin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u20131146.","journal-title":"Lancet"},{"key":"e_1_3_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_3_11_3_1","unstructured":"Lilly\u2019s ixekizumab met primary endpoint in a phase 3 study investigating the treatment of psoriatic arthritis. April 2015. [cited 2015 Jul 13]. (http:\/\/www.prnewswire.com\/news-releases\/lillys-ixekizumab-met-primary-endpoint-in-a-phase-3-study-investigating-the-treatment-of-psoriatic-arthritis-300068249.html)."},{"key":"e_1_3_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"e_1_3_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"e_1_3_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu237"},{"key":"e_1_3_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.210"},{"key":"e_1_3_11_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"e_1_3_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"e_1_3_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20162"},{"key":"e_1_3_12_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203419"},{"key":"e_1_3_12_5_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150132"},{"key":"e_1_3_12_6_1","unstructured":"Coates LC Moverly A McParland L et al. Results of a randomized control trial comparing tight control of psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. ACR meeting San Diego 2013. Abstract 814."},{"key":"e_1_3_13_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000140"},{"key":"e_1_3_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.138"},{"key":"e_1_3_13_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu461"},{"key":"e_1_3_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22331"},{"key":"e_1_3_13_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"e_1_3_13_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"e_1_3_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37876"},{"key":"e_1_3_13_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082925"},{"key":"e_1_3_13_10_1","unstructured":"Ritchlin C Gottlieb A McInnes I et al. Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase III multicenter double-blind placebo controlled study. ACR. 2012; abstract 2557."},{"key":"e_1_3_13_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"e_1_3_13_12_1","first-page":"1881","article-title":"The evolving use of TNF inhibitors in rheumatoid arthritis","volume":"31","author":"Kavanaugh A","year":"2004","unstructured":"Kavanaugh A, Cohen S, Cush J. The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol. 2004;31:1881\u20131884.","journal-title":"J Rheumatol"},{"key":"e_1_3_13_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"e_1_3_13_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu415"},{"issue":"28","key":"e_1_3_13_15_1","first-page":"S21","article-title":"Is there a rationale for combined TNF and IL-1 blocking in arthritis?","volume":"20","author":"Van Den Berg WB","year":"2002","unstructured":"Van Den Berg WB. Is there a rationale for combined TNF and IL-1 blocking in arthritis? Clin Exp Rheumatol. 2002;20(Suppl. 28):S21\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_13_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38896"},{"key":"e_1_3_13_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316133"},{"key":"e_1_3_13_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S31145"},{"key":"e_1_3_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1722-5"},{"key":"e_1_3_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1542-z"},{"key":"e_1_3_13_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203302"},{"key":"e_1_3_13_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206435"},{"key":"e_1_3_13_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken059"},{"key":"e_1_3_13_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283524e4c"},{"key":"e_1_3_13_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204223"},{"key":"e_1_3_13_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000342180"},{"key":"e_1_3_13_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000152"},{"key":"e_1_3_13_28_1","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kev239","article-title":"The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs","author":"Radner H","year":"2015","unstructured":"Radner H, et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology. 2015;54:2076\u20132084.","journal-title":"Rheumatology"},{"key":"e_1_3_13_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket454"},{"key":"e_1_3_13_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812"},{"key":"e_1_3_13_31_1","article-title":"Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative","author":"Roubille C","year":"2015","unstructured":"Roubille C, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol. 2015;42:1767\u20131780. Available from: http:\/\/www.jrheum.org.proxy1.lib.uwo.ca\/content\/early\/2015\/07\/10\/jrheum.141112.","journal-title":"J Rheumatol"},{"key":"e_1_3_14_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken320"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14712598.2016.1118045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:49:57Z","timestamp":1772772597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14712598.2016.1118045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1517\/14712598.2016.1118045"],"URL":"https:\/\/doi.org\/10.1517\/14712598.2016.1118045","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}